TM Owner Incyte Biosciences Distribution B.V.
Minjuvi 200mg Vial
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Minjuvi (tafasitamab) 200 mg is a CD19-directed monoclonal antibody supplied as a powder for concentrate for solution for infusion; it is the EU/international brand name for the same active substance marketed in the United States as Monjuvi (tafasitamab-cxix).
- Minjuvi is indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant, with tafasitamab continuing as monotherapy after the lenalidomide combination phase; it is also indicated, in combination with lenalidomide and rituximab, for adults with relapsed or refractory follicular lymphoma who have received at least one prior systemic therapy.
- Minjuvi is given only by intravenous infusion in a hospital or specialist oncology clinic under the supervision of a healthcare provider experienced in cancer treatment; it is not a self-administered medicine.
Side Effects
- Minjuvi carries no boxed warning on the current EU or US label, but it has several important warnings that require close monitoring.
- Very common side effects, affecting more than 1 in 10 patients, include infections (bacterial, viral and fungal), low white blood cell and platelet counts, rash, fatigue, swelling of the limbs, fever, diarrhoea, constipation, nausea, vomiting, cough and breathlessness.
- Infusion-related reactions occur in about 6% to 16% of patients, usually during the first cycles, with symptoms such as chills, flushing, breathlessness, high blood pressure and rash; these are managed by slowing or stopping the infusion and giving pre-treatment medicines such as paracetamol, antihistamines and corticosteroids before subsequent doses.
- Serious infections, including some fatal cases, have occurred, so patients should report fever, chills, cough or any new infection symptom immediately during and after treatment.
Precautions & Warnings
- Before and during Minjuvi treatment, full blood counts are checked regularly because of the risk of low white blood cell and platelet counts, and doses may be delayed or reduced if counts fall too low.
- Patients are monitored closely during and after each infusion for infusion-related reactions, with resuscitation equipment available.
- Serious and sometimes fatal infections have occurred, so active, untreated infections should be managed before starting treatment, and patients should be monitored for signs of progressive multifocal leukoencephalopathy, a rare but serious brain infection, particularly if neurological symptoms develop.
- Tumour lysis syndrome, caused by rapid breakdown of cancer cells, has also been reported and requires monitoring of blood chemistry, especially early in treatment.
- Because Minjuvi is always given together with lenalidomide, and sometimes with rituximab, the separate warnings, contraindications and pregnancy-prevention requirements of those medicines also apply.
- Safety in pregnancy has not been established; effective contraception is required during and after treatment.
Avoid Interactions
- No formal cytochrome P450 drug-interaction studies have been conducted with tafasitamab, as it is a monoclonal antibody and is not metabolised by liver enzymes in the way small-molecule drugs are, so classic CYP-based interactions are not expected.
- However, Minjuvi is always given in combination with lenalidomide, and often with rituximab, and those medicines carry their own significant interactions, precautions and contraception requirements that must be followed alongside Minjuvi.
- Live vaccines should be avoided during treatment because of the combined immunosuppressive effect of tafasitamab, lenalidomide and any recent rituximab.
- Tell the treating team about all other medicines, supplements and any recent or planned vaccinations before starting Minjuvi, since concurrent immunosuppressive or myelosuppressive treatments may need closer blood-count monitoring.
- Minjuvi must not be mixed or co-infused with other medicines in the same intravenous line; a dedicated line and an in-line filter are used as instructed by the treating hospital.
References
Frequently Asked Questions
Minjuvi (tafasitamab) treats adults with relapsed or refractory diffuse large B-cell lymphoma, given with lenalidomide, and relapsed or refractory follicular lymphoma, given with lenalidomide and rituximab. It is the international brand name; in the US the same drug is called Monjuvi.
Minjuvi is given as an intravenous infusion in hospital, usually weekly for the first cycles and then every two weeks in later cycles, alongside lenalidomide capsules. A healthcare provider decides the exact schedule based on your lymphoma type and response.
Infections, low blood cell counts, fatigue, rash and swelling are very common, each affecting more than 1 in 10 people. Infusion reactions such as chills, flushing and breathlessness occur in up to 16% of patients, mostly during early cycles, and are managed by the infusion team.
Avoid live vaccines during treatment, since Minjuvi combined with lenalidomide lowers your immune defences. Report any sign of infection, such as fever or cough, straight away. Effective contraception is required throughout treatment, because it is always given with lenalidomide.
You are monitored closely during and after each infusion for reactions such as fever, chills, flushing or breathlessness. You may be given paracetamol, an antihistamine and a steroid beforehand to reduce this risk, especially before your first few doses.
Yes. Minjuvi and Monjuvi both contain tafasitamab and work the same way; Minjuvi is the brand name used in the EU and other international markets, while Monjuvi is used in the United States. Approved combinations and monitoring requirements are the same.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
